Close menu

January 27th, 2022 | 10:13 CET

Valneva, XPhyto, Peloton Interactive: What is next for pandemic stocks?

  • Biotechnology
Photo credits:

The pandemic is entering a new phase. Although incidences are rising towards the 1,000 mark, the population is largely relaxing. In the meantime, almost everyone knows someone who has fallen ill; as a rule, the scare is over quickly for those who have been vaccinated. In this article, we look at what this means for the stock market.

time to read: 3 minutes | Author: Nico Popp
ISIN: VALNEVA SE EO -_15 | FR0004056851 , XPHYTO THERAPEUTICS | CA98421R1055 , PELOTON INTE.A DL-_000025 | US70614W1009

Table of contents:

    Valneva: What is the outlook for the hopeful Company?

    The Valneva share has recently lost ground. The European inactivated vaccine was eagerly awaited by many market participants in recent months. In the meantime, however, the air around the hopeful vaccine of many vaccination critics is out. The approval process for the French manufacturer's vaccine is currently underway within the EU. The vaccine may be approved before the end of the first quarter. Participants in the ongoing Phase III trial are already receiving the vaccine as a booster, but these data will no longer be included in the approval process in the short term. However, the data are not lost and could play a role in further approval procedures.

    A few days ago, it became known that Valneva's vaccine candidate probably also helps against the Omicron variant. However, the Company will not put its PS on the road until it is also approved. Since the proportion of unvaccinated people in Germany is still high, there is still sales potential for Valneva. In a market phase in which Corona profiteers are being punished across the board, the shares of the vaccine laggard are not the first choice.

    XPhyto: PCR-quality rapid tests gain in importance

    Another laggard is the share of the biotech XPhyto - at least as far as the share price is concerned, the value has hardly profited recently. Yet XPhyto offers precisely what could help in the current phase of the pandemic: Rapid PCR tests that promise laboratory-quality results within 25 minutes - and completely independent of location. In addition, XPhyto's Diagnostics business offers products to combat oral diseases and is researching innovative dosage forms. In this business area, the aim is to enable certain active ingredients to be better absorbed by the body if they are administered in the form of patches instead of tablets, for example. These approaches can, for example, ensure that the overall dose can be increased, which can, for example, reduce susceptibility to side effects. As a third pillar, XPhyto offers psychedelics for use against mental illness. Research of this kind is quite normal in the US but is viewed critically in Europe because some of the active ingredients are also considered narcotics.

    The share has lost ground in recent weeks, probably because PCR tests are now to be rationed in Germany. However, it remains to be seen to what extent these requirements can be implemented in practice. Since rapid tests are still considered unreliable, and experts warn of new virus variants, the pandemic is not yet over on the stock market. XPhyto's stock remains interesting, above all, because there are also countries where PCR tests have long been the gold standard, such as Austria. The research portal took a closer look at XPhyto a few months ago.

    Peloton: Now this too!

    A pandemic stock of the first hour is Peloton Interactive. When the epidemic was still comparatively young, Corona felt like a big "challenge" to many people. Resign and get fat or get through it was the name of the game. Many self-optimizers learned languages, an instrument or swung onto a spinning bike in the first few weeks. Peloton offers such a bike, including motivation from experienced trainers via stream. But recently, the stock dropped like a stone. Peloton's existing users also appear pandemic-weary. To make matters worse, a series character from "Sex and the City" has now "died" after a Peloton workout - purely fictitiously, of course. But this example shows that product placement can backfire. Peloton's stock is not very interesting at the moment. Spring is just around the corner in the northern hemisphere. Those who want to do sports will soon be doing so outside again. Incidence or not.

    While Peloton may have seen its highs, XPhyto and Valneva could go up again. The pandemic is not over yet, but it is changing its face. Speculative XPhyto, in particular, could react dynamically to new orders.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author

    Related comments:

    Commented by Stefan Feulner on June 6th, 2023 | 07:15 CEST

    MediGene, BioNTech, BioNxt Solutions - New opportunities after the correction

    • Biotechnology
    • Pharma
    • Cancer

    Acquisitions by big pharma were increasingly expected in the biotechnology sector last year, but these largely failed to materialize. However, this trend could accelerate in the current year. On the one hand, pharmaceutical companies, such as the vaccine manufacturer Pfizer, have deep pockets and need new innovations for their product portfolio. On the other hand, second-tier stocks are attractive targets due to the strong correction.


    Commented by Juliane Zielonka on June 1st, 2023 | 09:30 CEST

    BioNxt Solutions, Bayer, Palantir - AI is dominating the market at breathtaking speed and ensuring high returns

    • Biotechnology
    • Pharma
    • AI

    Tech investors have suffered heavy losses over the past year. But tech in pharma and security in defence enables entirely new future scenarios whose precise developments are worth examining more closely. For example, gentler and more effective new ways that benefit patients are emerging in the drug delivery market. At the forefront is the Company BioNxt Solutions, which specializes in innovative transdermal patches whose active ingredients literally go under the skin. In Germany, the biotech company cooperates with a German pharmaceutical partner. New times are now dawning for Bayer as well. Under the new reign of CEO Bill Anderson, digital health seems to have finally found its positioning in the Consumer Health division. There, the Company is to cooperate with exciting start-ups that collect and analyze consumer data. When it comes to networking and interpreting data using AI, one company in particular stands out at the moment. Palantir is moving out to "dominate the entire market." How? Find out in the comments below.


    Commented by Fabian Lorenz on June 1st, 2023 | 08:45 CEST

    JinkoSolar, BioNTech and First Phosphate with important updates: This is what moves the shares

    • Mining
    • phosphate
    • photovoltaics
    • Biotechnology

    The energy transition is moving forward. In Germany, the traffic light government seems to have agreed on a new heating law. In the US, the agreement between Democrats and Republicans on the debt ceiling is a good sign for the industry because the promotion of environmentally friendly technologies depends on it. JinkoSolar and First Phosphate, among others, should benefit from this. Both companies have published important updates. There is also important news at BioNTech. However, these are not so positive. When will there be new impulses for the share?